NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form ...

Novo Nordisk (NVO) is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.34 billion, while the same for earnings is pinned at 83 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk’s 2024 earnings per share (EPS) declined from $3.28 to $3.16. During the same time frame, the ...

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the company's obesity treatment study results [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Moon v. Novo Nordisk A/S and covers purchasers of Novo Nordisk securities from November 2, 2022, to December 19, 2024 [1]. - Investors have until March 25, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Novo Nordisk executives made false statements about the success of the phase 3 CagriSema study, specifically regarding weight loss outcomes and dosage tolerability [3]. Group 2: Allegations Against Novo Nordisk - The lawsuit alleges that Novo Nordisk misrepresented the reliability of information regarding the CagriSema study's outcomes and failed to disclose critical details about dosage tolerability [3]. - It is claimed that the optimistic projections of achieving at least 25% weight loss were not met, and the study's flexible protocol limited the ability to provide accurate weight loss data [3]. - Following the release of the study results on December 20, 2024, Novo Nordisk's stock price fell nearly 18%, indicating a significant market reaction to the disclosed information [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Novo Nordisk securities during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [6].

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=126285&from=4CLASS PERIOD: November 2, 2022 to Dece ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NVO -1.04%), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area ...

SAN DIEGO, Jan. 31, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"), have until March 25, 2025 to seek appointment as lead plaintiff of the Novo Nordisk class action lawsuit. Captioned Moon v. Novo Nordisk A/S, No. 25-cv-00713 (D.N.J.), the Novo Nordisk class action lawsuit charges Novo Nordisk as well as certain of ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-for ...

Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1] Group 1: Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [1] - Only 57.3% of patients in the trial were on the highest dosage of CagriSema, as participants were allowed to modify their own dosage during the trial [1] Group 2: Stock Price Impact - Following the press release regarding the trial results, Novo's stock price decreased by $18.44 per share, closing at $85.00 per share [1] Group 3: Class Action Information - Shareholders who purchased shares of NVO during the class period from November 2, 2022, to December 19, 2024, are encouraged to register for a class action lawsuit [2] - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [2]

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly making false and misleading statements regarding the company's phase 3 CagriSema study on obesity, which may have misled investors during the class period from November 2, 2022, to December 19, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey on behalf of all individuals and entities who purchased Novo Nordisk securities during the specified class period [1]. - Investors have until March 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Novo Nordisk - The complaint alleges that the defendants created a false impression of possessing reliable information regarding the successful outcome of the CagriSema study while avoiding discussions on dosage tolerability [3]. - It is claimed that Novo Nordisk's optimistic assertions that CagriSema would achieve at least 25% weight loss in the REDEFINE-1 study did not align with actual results [3]. - The use of a "flexible protocol" in the study is said to have limited its ability to provide effective weight loss data, suggesting potential issues with dosage tolerability or a rushed patient selection process [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S regarding a class action lawsuit following disappointing results from the "REDEFINE 1" trial of CagriSema, which led to a significant drop in the company's stock price [1][3]. Group 1: Trial Results and Impact - The "REDEFINE 1" trial, which investigated the efficacy and safety of subcutaneous CagriSema, reported a weight loss of 22.7% after 68 weeks, falling short of Novo's target of at least 25% [3]. - Only 57.3% of patients in the trial were on the highest dosage, as participants were allowed to modify their own dosage during the study [3]. - Following the announcement of these results, Novo's stock price decreased by $18.44, closing at $85.00 per share [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 2, 2022, to December 19, 2024, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].